Satellos Bioscience Stock Debt To Equity
| MSCLF Stock | USD 0.48 0.03 5.88% |
Fundamental analysis of Satellos Bioscience allows traders to better anticipate movements in Satellos Bioscience's stock price by examining its financial health and performance throughout various phases of its business cycle.
Satellos |
Satellos Bioscience OTC Stock Debt To Equity Analysis
Satellos Bioscience's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Satellos Bioscience has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 100.0% higher than that of the company.
Satellos Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Satellos Bioscience's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Satellos Bioscience could also be used in its relative valuation, which is a method of valuing Satellos Bioscience by comparing valuation metrics of similar companies.Satellos Bioscience is currently under evaluation in debt to equity category among its peers.
Satellos Fundamentals
| Return On Equity | -0.86 | |||
| Return On Asset | -0.4 | |||
| Current Valuation | 7.17 M | |||
| Shares Outstanding | 41.8 M | |||
| Shares Owned By Insiders | 9.30 % | |||
| Shares Owned By Institutions | 14.41 % | |||
| Price To Book | 1.10 X | |||
| Price To Sales | 295.34 X | |||
| Gross Profit | (793.97 K) | |||
| EBITDA | (4.49 M) | |||
| Net Income | (15.51 M) | |||
| Cash And Equivalents | 1.93 M | |||
| Cash Per Share | 0.06 X | |||
| Current Ratio | 1.04 X | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (5.03 M) | |||
| Earnings Per Share | (0.47) X | |||
| Market Capitalization | 15.29 M | |||
| Total Asset | 12.59 M | |||
| Net Asset | 12.59 M |
About Satellos Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Satellos Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satellos Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satellos Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Satellos OTC Stock
Satellos Bioscience financial ratios help investors to determine whether Satellos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Satellos with respect to the benefits of owning Satellos Bioscience security.